112 related articles for article (PubMed ID: 37151057)
1. Design of Novel Imidazopyrazine Derivative against Breast Cancer
Niranjan V; R V; Philip S; Uttarkar A; Kusanur R; Kumar J
Anticancer Agents Med Chem; 2023; 23(15):1783-1793. PubMed ID: 37151057
[TBL] [Abstract][Full Text] [Related]
2. Design of Novel Coumarin Derivatives as NUDT5 Antagonists That Act by Restricting ATP Synthesis in Breast Cancer Cells.
Niranjan V; Jayaprasad S; Uttarkar A; Kusanur R; Kumar J
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615284
[TBL] [Abstract][Full Text] [Related]
3. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents.
Dolatkhah Z; Javanshir S; Sadr AS; Hosseini J; Sardari S
J Chem Inf Model; 2017 Jun; 57(6):1246-1257. PubMed ID: 28524659
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
6. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Characterization, Molecular Docking, In Vitro Biological Evaluation and In Vitro Cytotoxicity Study of Novel Thiazolidine-4-One Derivatives as Anti-Breast Cancer Agents.
Kadhim ZY; Alqaraghuli HGJ; Abd MT
Anticancer Agents Med Chem; 2021; 21(17):2397-2406. PubMed ID: 33797379
[TBL] [Abstract][Full Text] [Related]
8. Novel 1,2,4-triazole derivatives: Design, synthesis, anticancer evaluation, molecular docking, and pharmacokinetic profiling studies.
Turky A; Sherbiny FF; Bayoumi AH; Ahmed HEA; Abulkhair HS
Arch Pharm (Weinheim); 2020 Dec; 353(12):e2000170. PubMed ID: 32893368
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
10. QSAR studies on imidazopyrazine derivatives as Aurora A kinase inhibitors.
Leng Y; Lu T; Yuan HL; Liu HC; Lu S; Zhang WW; Jiang YL; Chen YD
SAR QSAR Environ Res; 2012 Oct; 23(7-8):705-30. PubMed ID: 22971111
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers.
Khade AB; Kar SS; Alummoottil CT; Tiwari A; Tiwari M; Eshwara VK; Bhat P; Giliyar VB; Shenoy GG
Med Chem; 2020; 16(2):256-270. PubMed ID: 30848207
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects.
Elkaeed EB; Yousef RG; Elkady H; Gobaara IMM; Alsfouk BA; Husein DZ; Ibrahim IM; Metwaly AM; Eissa IH
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889478
[TBL] [Abstract][Full Text] [Related]
13. A computational strategy to understand structure-activity relationship of 1,3-disubstituted imidazole [1,5-α] pyrazine derivatives described as ATP competitive inhibitors of the IGF-1 receptor related to Ewing sarcoma.
Guaitoli V; Alvarez-Ginarte YM; Montero-Cabrera LA; Bencomo-Martínez A; Badel YP; Giorgetti A; Suku E
J Mol Model; 2020 Aug; 26(8):222. PubMed ID: 32748063
[TBL] [Abstract][Full Text] [Related]
14. Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents.
Santoshi S; Manchukonda NK; Suri C; Sharma M; Sridhar B; Joseph S; Lopus M; Kantevari S; Baitharu I; Naik PK
J Comput Aided Mol Des; 2015 Mar; 29(3):249-70. PubMed ID: 25481458
[TBL] [Abstract][Full Text] [Related]
15. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
Kalirajan R; Pandiselvi A; Gowramma B; Balachandran P
Curr Drug Res Rev; 2019; 11(2):118-128. PubMed ID: 31513003
[TBL] [Abstract][Full Text] [Related]
16. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
18. Novel p-Functionalized Chromen-4-on-3-yl Chalcones Bearing Astonishing Boronic Acid Moiety as MDM2 Inhibitor: Synthesis, Cytotoxic Evaluation and Simulation Studies.
Bhatia RK; Singh L; Garg R; Kaur M; Yadav M; Madan J; Kancherla S; Pissurlenkar RRS; Coutinho EC
Med Chem; 2020; 16(2):212-228. PubMed ID: 31146672
[TBL] [Abstract][Full Text] [Related]
19. Chloro and bromo-pyrazole curcumin Knoevenagel condensates augmented anticancer activity against human cervical cancer cells: design, synthesis,
Chaudhary M; Kumar N; Baldi A; Chandra R; Arockia Babu M; Madan J
J Biomol Struct Dyn; 2020 Jan; 38(1):200-218. PubMed ID: 30784365
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative and Pro-Apoptotic Effects of Thiazolo[3,2-b][1,2,4]triazoles in Breast and Cervical Cancer Cells.
Khan I; Zaib S; Javed M; Rashid F; Iqbal J; Ibrar A
Anticancer Agents Med Chem; 2021 Oct; 21(16):2181-2191. PubMed ID: 33573578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
